Baxalta
 | |
| Subsidiary | |
| Industry | Biotechnology |
| Fate | Acquired by Shire |
| Founded |
2015 Spun off from Baxter International |
| Defunct | 2016 |
| Products | Hematology, Immunology, Pulmonology |
Number of employees | 16,000[1] |
| Website |
www |
Baxalta (Bax, taken from its former parent company and Alta taken from the Latin Altus which translates as 'high' or 'profound'[2]) was a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division.[1][3] with revenue of $6 billion.
Company History
Baxalta inherited all of its parent company's on-the-market treatments, focused on hemophilia, The company aims to launch 20 in-development projects by 2020, heaping $2.5 billion in annual sales. Before being spun off, Baxalta acquired SuppreMol (a German company) for US$225 million.[4] Baxalta also acquired the blockbuster leukemia drug Oncaspar from Sigma-Tau Finanziaria S.p.A. for US$900 million.[1][5]
In August 2015, Shire Plc made an unsolicited $30.6 billion stock offer for the company[6][7] increasing the Baxalta share price over 16%. Baxalta investors would be set to receive 0.1687 of Shire's American Depositary Receipts for every share they hold, representing a premium of 36%, compared to the company's stock price on August 3.[8] This deal would create the largest global biotech company focused solely on rare diseases.[8]
In January 2016, after 6 months of negotiations, the company agreed to be acquired by Shire for $32 billion.[9] Shareholders have approved of the transaction and the deal is planned to close on 3 June 2016.[10] The deal was completed on June 3rd 2016.
Pipeline
- Hematology
- BAX 855 – long-acting pegylated full-length rFVIII[11] hemophilia A drug awaiting FDA approval in conjunction with Nektar Therapeutics.[12] It is also undergoing Phase II trials for sickle cell.[13]
- BAX 111 – submitted as a recombinant von Willebrand factor treatment for von Willebrand disease, filed with the FDA in December 2014.[14] In August 2015, data was released and published in the journal Blood,[15] which indicated that 100 percent of the patients treated with BAX 111 were successful in the management of bleeding episodes.[16][17]
- BAX 817 – Recombinant factor VIIa[13]
- BAX 335 – FIX gene therapy in Phase II.[13]
- BAX 930 – Recombinant ADAMTS13[13]
- BAX 826 – Recombinant, extended half-life Factor VIII[13]
- BAX 888 – Factor VIII gene therapy in Phase I trials.[13]
- Immunology
- BAX 2200 – Psoriasis drug in Phase III.[13]
- SM101 - As of 2015, had completed Phase IIA studies in idiopathic thrombocytopenic purpura[4][13]
- SM201 / SM211[13]
- SM301[13]
- BAX 923 – a biosimilar version of Adalimumab.[13]
- BAX 1415[13]
- Oncology
- MM-398 – Co-developed with Merrimack Pharmaceuticals.[18] Undergoing EU reviews for post-Gemcitabine pancreatic cancer, in Phase III trials for gastric cancer[13] Currently undergoing priority review with the FDA[19] for a new drug application.[20][21]
- Pacritinib – Phase III trials for Myelofibrosis, Phase I trials for Acute Myeloid Leukemia and pre-clinical for Chronic Lymphocytic Leukemia, Myelodysplastic Syndrome and Polycythemia Vera.[13]
- Rigosertib – Phase III trials for Myelodysplastic Syndrome.[13]
- BAX 069 – also known as Imalumab, in Phase II trials for Malignant Ascites and Metastatic Colorectal cancer.[13]
References
- 1 2 3 Ben Reynolds. "Baxalta: A Rare Undervalued Biopharmaceutical Company". cnafinance.com.
- ↑ "An Error Occurred Setting Your User Cookie". future-science.com.
- ↑ "Baxalta: Baxter's newly named biopharma spinout has had its ups and downs". FierceBiotech.
- 1 2 Staff (1 April 2015). "Baxter Acquires SuppreMol and Its Immunoregulatory Therapy Pipeline". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). 35 (7): 10.
- ↑ "Baxter Expands Cancer Therapies With $900M Oncaspar Buy". law360.com.
- ↑ Tess Stynes (4 August 2015). "Shire Makes Unsolicited $30 Billion Bid for Baxalta". WSJ.
- ↑ "Shire Offers $30B for Baxalta". GEN.
- 1 2 Kevin McCoy, USA TODAY (4 August 2015). "Pharma mania: Shire offers $30B for Baxalta". USA TODAY.
- ↑ http://www.genengnews.com/gen-news-highlights/shire-baxalta-tie-the-knot-in-32b-merger/81252213/
- ↑ DeMuth, Jr., Chris (27 May 2016). "Facebook Is Watching You". Seeking Alpha. Baxalta. Retrieved 2016-05-27.
- ↑ "Blood Journal - Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A". bloodjournal.org.
- ↑ "Baxalta & Nektar Reveal Full Data from Hemophilia Study - Analyst Blog". NASDAQ.com. 17 July 2015.
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 "Pharmaceutical Development Pipeline - Baxalta". baxalta.com.
- ↑ "Baxalta's first-of-its-kind bleeding drug lines up for FDA approval". FierceBiotech.
- ↑ "Blood Journal - Hemostatic efficacy, safety and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease". bloodjournal.org.
- ↑ "Blood Publishes Phase III Data on Baxalta's Investigational Treatment for Von Willebrand Disease, the Most Common Type of Inherited Bleeding Disorder". Yahoo Finance. 3 August 2015. Archived from the original on 2015-08-19.
- ↑ "Blood Publishes Phase III Data on Baxalta's Investigational Treatment for Von Willebrand Disease, the Most Common Type of Inherited Bleeding Disorder - Business Wire". businesswire.com. 3 August 2015.
- ↑ "MM-398". merrimackpharma.com.
- ↑ Merrimack Pharmaceuticals, Inc. (25 June 2015). "U.S. FDA Grants Priority Review for MM-398 New Drug... -- CAMBRIDGE, Mass. and DEERFIELD, Ill., June 25, 2015 /PRNewswire/ --". prnewswire.com.
- ↑ "U.S. FDA Grants Priority Review for MM-398 New Drug Application". merrimackpharma.com.
- ↑ "Oncology Times". LWW.